Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan
Authors:
Open Access
- 21 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 87 (7) , 734-740
Abstract
Background: Radium-223 dichloride (Ra-223) prolongs overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases. However, there is considerable variation in outcomes among individuals. We aimed to evaluate the prognostic determinants associated with patient survival following National Health Insurance (NHI) reimbursement for Ra-223 therapy in Taiwan. Methods: Patients with mCRPC who underwent Ra-223 treatment at Taipei Veterans General Hospital were retrospectively enrolled. Each intravenous Ra-223 dose was administered at 55 kBq/kg at 4-week intervals. Clinical outcomes were obtained from medical records; potential prognostic factors for survival were assessed. Kaplan-Meier analysis was used to generate cumulative survival curves; between-group differences were evaluated using the Chi-squared test. Statistical significance was set at p < 0.05. Results: Seventy-six patients underwent Ra-223 therapy; 62 patients received NHI reimbursement and the remainder self-paid. Fifty patients (65.8%) completed six cycles of treatment; 26 (34.2%) received 1 to 5 cycles. Mortality occurred in 47 patients. Factors significantly associated with survival included ≤five bone metastases (p = 0.0018), baseline prostate-specific antigen (PSA) ≤36 ng/mL (p = 0.0004), baseline alkaline phosphate (ALP) 12 g/dL (p = 0.0029). Patients who completed six cycles of treatment achieved significantly higher OS compared to those who did not (p < 0.0001). There has been a 4.4-fold increase in the number of patients since reimbursement began; there was no significant difference in OS between patients who received NHI reimbursement and those who self-paid. Conclusion: Administration of Ra-223 demonstrates considerable potential to extend the survival of patients with mCRPC. Survival outcomes may be influenced by various prognostic factors. However, no significant difference in OS was observed subsequent to reimbursement of Ra-223 therapy for mCRPC through the NHI system in Taiwan.Keywords
This publication has 24 references indexed in Scilit:
- Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in TaiwanJournal of the Formosan Medical Association, 2022
- Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate CancerClinical Oncology, 2018
- Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate CancerClinical Genitourinary Cancer, 2017
- Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastasesInternational Journal of Clinical Oncology, 2017
- Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerCurrent Oncology Reports, 2016
- Factors affecting 223Ra therapy: clinical experience after 532 cycles from a single institutionEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialThe Lancet Oncology, 2014
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- 714 PAIN AND QUALITY OF LIFE (QOL) ANALYSES FROM THE PHASE 3 RANDOMIZED ALSYMPCA STUDY WITH RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS WITH BONE METASTASESJournal of Urology, 2013
- 223Ra targets skeletal metastases and spares normal tissueThe Lancet Oncology, 2002